My experience as an emergency medicine physician offers perspective in my research. A significant portion of patients I saw were those whose diseases were not well controlled. While this may have been due to socioeconomic issues or limited access to physicians, most often, it was because treatments for their conditions were not ideal or simply did not exist.
Despite a challenging few years for biotechnology stocks, the sector continues to offer exciting possibilities - for investors and individuals in need of innovative medical treatments. In the year ahead, trends such as accelerated biotech M&A activity and gradually easing interest rates could help move the sector out of its slump.
However, rather than looking for factors that might lift all boats, our focus remains on finding companies with underappreciated assets that target unmet medical needs.
